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A single cell has the potential to kill an entire human being. Efforts to cure cancer are limited by survival of individual cancer cells 
despite immune surveillance and toxic therapies. Understanding the intricate network of pathways that maintain cellular homeo-
stasis and mediate stress response or default into cell death is critical to the development of strategies to eradicate cancer. Au-
tophagy, proteasomal degradation and the unfolded protein response (UPR) are cellular pathways that degrade and recycle excess 
or damaged proteins to maintain cellular homeostasis and survival. This review will discuss autophagy and how it is integrated with 
proteasomal degradation and UPR to govern cell fate through restoration of cellular homeostasis or default into the apoptotic cell 
death pathway. The first response of autophagy is macroautophagy, which sequesters cytoplasm including organelles inside double-
membraned autophagosome vesicles that fuse with lysosomes to degrade and recycle the contents. Ubiquitination patterns on pro-
teins targeted for degradation determine whether adapter proteins will bring them to developing autophagosomes or to proteasomes. 
Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds 
proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane 
protein type 2A) receptor. These two processes and the lesser understood microautophagy, which involves direct engulfment of pro-
teins into lysosomes, occur at basal and induced levels. Insufficient proteasome function or ER stress induction of UPR can induce 
autophagy, which can mitigate damage and stress. If this network is incapable of repairing the damage or overcoming continued 
stress, the default pathway of apoptosis is engaged to destroy the cell. Induction of macroautophagy by cancer therapeutics has led 
to clinical trials investigating combinations of HCQ (hydroxychloriquine) suppression of autophagy with apoptosis-inducing agents. 
Further study of the complex integration of autophagy, proteasomal degradation, UPR and apoptosis is likely to provide addi-
tional targets for our fight against cancer. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
Understanding how cells die is critical knowledge 
needed for the development of health care strategies 
to prevent the death of cells in degenerative and acute 
diseases and to induce the death of diseased cells that 
can harm the body if not eliminated. Both morphologi-
cal and molecular events that occur in dying cells have 
been characterized and categorized into 13 current 
modes [37, 68]. More recently, an iron-dependent 
form of non-apoptotic death termed “ferroptosis” has 
been described [30]. Autophagy, which was officially 
identified and named by Christian de Duve in 1963 [22, 
59], is formally classified as a form of cell death, how-
ever the majority of evidence implicates autophagy 
as a mechanism to maintain cellular homeostasis and 
recover from stress, while unequivocal evidence that 
autophagy causes cell death is rare. The survival func-
tion is accomplished through digestion of long-lived 
or damaged proteins and organelles and release of the 
components for recycling. The death function is be-
lieved to be caused by excessive digestion of cellular 
components or selective digestion of survival factors 
over death factors. This review will discuss the integra-
tion of autophagy with other cellular processes that 
maintain homeostasis and mediate stress responses 
leading to cancer cell survival or death, sometimes 
through apoptosis, and how these mechanisms are 
being targeted to improve cancer therapy. For more 
details on the mechanism of autophagy, readers are 
directed to several recent reviews [7, 75, 76, 112, 123].
FORMS OF AUTOPHAGY
There are three natural processes of autophagy 
in the cell,  MA (macroautophagy),  CMA (chaperone-
mediated autophagy) and microautophagy. Mac-
roautophagy is a natural process in which portions 
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of the cytoplasm, including long-lived proteins and 
organelles, are sequestered inside double-membraned 
vesicles called autophagosomes. The autophagosomes 
eventually fuse with lysosomes to form autophagoly-
sosomes where the contents are digested and their 
components released for recycling within the cells. CMA 
is driven by Hsc70 (heat shock cognate 70, also called 
HSPA8 [heat shock protein A8]), which binds specific 
proteins and transports them directly into the lysosome 
[76]. In microautophagy, defective molecules or organ-
elles are directly engulfed into the lysosomes for degra-
dation and recycling of their components [75]. All three 
forms of autophagy occur at basal levels to maintain 
the cell, while suprabasal levels are induced by nutrient 
or oxygen deprivation, endoplasmic reticulum stress, 
proteasome malfunction or damage caused by drugs 
or radiation. Most articles refer to macroautophagy 
as autophagy, however because this article addresses 
all three forms of autophagy in detail, the term macro-
autophagy is used herein to describe the specific pro-
cess of autophagosome-mediated recycling. The term 
autophagy is used in situations where it is feasible that 
all three forms of autophagy could be actively involved 
in the process under discussion.
MECHANISM, MEASUREMENT AND 
MANIPULATION OF MACROAUTOPHAGY
The production and processing of autophagic ves-
icles is divided into 4 steps: 1) initiation, 2) nucleation, 
3) maturation and 4) fusion with lysosomes (Fig. 1). 
These processes are mediated by a series of proteins 
encoded by autophagy-related genes (ATGs), which 
were originally characterized in yeast, and are highly 
conserved in higher eukaryotes [60].
During initiation, de novo synthesis of isolation 
membranes recruits lipids from several organelles 
depending on the cell type and stimulus. Electron 
micrograph documentation of ER located on both 
sides of isolation membranes, and what appears 
to be a single bridge connecting the ER to the isola-
tion membrane, indicate that this organelle is a source 
of membrane lipids for the de novo formation 
of autophagosomes in the cytoplasm [42]. Formation 
of isolation membranes from the mitochondria ap-
pears to be dependent upon PS (phosphatidylserine) 
transfer from the ER to the mitochondria [41]. The 
mitochondrial enzyme, PS decarboxylase, converts 
PS to PE (phosphatidylethanolamine), which is needed 
for autophagosome formation as described below 
[113]. Proteins associated with only the outer leaflet 
of the mitochondrial membrane appear to transfer 
to the autophagosome, while proteins that traverse the 
entire mitochondrial membrane are retained in the mi-
tochondria [41]. The plasma membrane has also been 
shown to contribute lipids to the initiation membrane 
through a process dependent upon the interaction 
of clatherin on the plasma membrane with Atg16L 
on the forming autophagosome [100]. An alternative 
form of macroautophagy shown to occur during fetal 
development and erythroid maturation derives mem-
brane lipids for de novo autophagosome formation 
from the trans-Golgi and late endosomes [87].
The complex of proteins that mediate initiation con-
sists of ULK1 (uncoordinated 51-like kinase 1/Atg1), 
Atg13 and FIP200 (focal adhesion kinase interacting 
protein of 200 kD/Atg17). Basal levels of macroau-
tophagy are kept in check by mTORC1 (mamma-
lian target of rapamycin complex 1) phosphorylation 
of Atg13 and ULK1, which inhibits ULK1 phosphoryla-
tion of FIP200 [12, 38, 44, 49]. The mTORC1 complex 
is an important component of a network that senses 
the nutrient state of the cell and accordingly controls 
the levels of anabolism and catabolism to maintain 
homeostasis [46] (Fig. 2). High levels of amino acids 
maintain mTORC1 in an active state by enhancing bind-
ing of this complex to regulatory proteins Rag and Rheb 
(Ras homolog enriched in brain) GTPases (guanosine 
triphosphatases) [56, 105]. Insulin and IGF1 (insulin 
like growth factor 1) indirectly induce mTORC1 activity 
by stimulating class 1 PI3K (phosphoinositol 3-kinase) 
production of PIP3 (PtdIns(3,4,5)P3), which induces 
the Akt kinase at the plasma membrane, which in turn 
activates mTORC1 by inhibiting TSC (tuberous sclero-
sis complex) proteins 1 and 2, thereby relieving their 
repression of Rheb [4, 8]. Low glucose levels or high 
levels of AMP (adenosine 5’-monophosphate), which 
indicate low cellular energy status or stress, activate 
AMPK (AMP-activated protein kinase), which inhibits 
mTORC1 and stimulates macroautophagy [46, 95]. 
In summary, high levels of amino acids, insulin and 
IGF-1 inhibit macroautophagy by inducing the PI3K/
Akt/mTORC1 pathway, while low glucose and high 
AMP levels induce autophagy by activating the AMPK 
and repressing mTORC1 activity (Fig. 2). Chemical 
inhibitors of mTORC1 currently in clinical use or in clini-
cal trials, including rapamycin and analogs called 
Fig. 1. Simplified Illustration of macroautophagy
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rapalogs, such as Everolimus (RAD001), induce 
macroautophagy and are often used as tools to study 
autophagy [10, 57]. As discussed below, this induction 
of macroautophagy interferes with the clinical efficacy 
of these drugs as anti-cancer agents.
Nucleation is controlled by a class III PI3K called 
Vps34 (vacuolar protein sorting 34) that forms a com-
plex with Beclin 1 (Atg6/Vp330), p150 (Vps15) and 
Atg14L [79]. Production of PIP3 by Vps34 recruits WIPI 
(WD40 repeat protein Interacting with phosphoInositi-
des/Atg18) proteins to the isolation membrane allow-
ing recruitment of LC3 (light chain of the microtubule-
associated protein 1/ Atg8) and further evolution of the 
autophagosome [97]. While specific inhibition of class 
I PI3K stimulates macroautophagy indirectly through 
downstream Akt/mTOR inhibition, specific inhibi-
tion of class III PI3K Vps34 inhibits macroautophagy 
through reduction of an autophagy-specific PIP3 pool 
[95]. As discussed below, nucleation can also be inhib-
ited by binding of the anti-apoptotic protein Bcl-2 (B-
Cell CLL/Lymphoma 2) to Beclin 1 [94]. 
Two interdependent ubiquitin-like conjugation sys-
tems mediate the maturation (elongation, curvature 
and closure) of the autophagosome. In one system, 
LC3 is first cleaved by the Atg4 serine protease and 
then conjugated to PE by the Atg7 and Atg3 enzymes 
[45]. The unmodified and lipidated forms of LC3 are 
termed LC3-I and LC3-II, respectively, and can be dis-
tinguished by Western blot analysis, a well accepted 
method to monitor macroautophagy [6]. The second 
system recruits LC3-II to the isolation membrane by the 
ubiquitin-like activity of Atg12, which is covalently bound 
to Atg5 and physically associated with Atg-16L to form 
a complex [86]. Once the isolation membrane is formed, 
the Atg-12, -5, -16L complex is released, which affords 
it’s utilization as a marker of isolation membrane forma-
tion [86]. LC3-II on the other hand, remains associated 
with the autophagosome until fusion with the lyso-
some, and the transition of diffuse to punctuate pattern 
of a transfected LC3-green fluorescent protein fusion 
protein in the cytoplasm is a commonly used marker 
of autophagosome formation [6, 86]. 
Before fusion with the lysosome, ubiquitinated 
proteins can be brought to the inside of the develop-
ing autophagosome by adapter proteins. Proteins are 
targeted for degradation by E1, E2 and E3 ubiquiti-
nases that attach the C-terminal glycine on ubiquitin 
to the ε-amino group of a lysine residue in the protein 
being targeted [96]. Multiple molecules of ubiquitin 
can be added to the same protein as individual com-
ponents, and to Lys residues on existing ubiquitins 
that are already present on the target proteins to form 
branched chains [119]. Adapter proteins/macro-
autophagy receptors called p62, NBR1 (neighbor 
of BRC1), HDAC6 (histone deacetylase 6) and Alfy bind 
the ubiquitinated proteins and bring them inside devel-
oping autophagosomes [98, 121]. HDAC6 is a micro-
tubule associated acetylase that binds to, and utilizes, 
dynein motors to transport ubiquitinated proteins along 
microtubles to a structure called the aggresome where 
they are recognized by developing autophagosomes 
[53]. As discussed below, the pattern of ubiquitina-
tion will determine whether the protein is targeted for 
autophagic versus proteasomal degradation [98, 121]. 
The fusion step is mediated by dynein transpor-
tation of the autophagosomes along microtubules 
to fuse with endosomes or lysomes [99]. Microtu-
bule disrupting agents, such as taxanes, vinblastine 
or nocodazole, can prevent the fusion and cause 
accumulation of autophagic vacuoles [32]. Inhibition 
of lysosomal acidification by Bafilomycin A, a specific 
V-ATPase (vacuolar H+ ATPase) inhibitor, or by other 
lysosomal function inhibitors, CQ (Chloroquine) and 
HCQ (hydroxychloroquine), also cause accumula-
tion of autophagosomes [122, 126]. Upon fusion with 
the lysosome, the contents are degraded and the 
components, including amino acids and lipids, are 
released for re-utilization in cellular metabolism. The 
TCA (tricarboxylic acid) cycle, which utilizes amino 
acids for generation of bioenergetic molecules and 
Fig. 2. Integration of macroautophagy with the regulatory network controlling the maintenance of cellular homeostasis versus 
apoptosis. The Grp78 under ER stress has two effects, increased Grp78 expression induces autophagic vesicle formation while 
release of Grp78 inhibition of PERK, EIF2α and ATF6 induce UPR. ATF4 is listed next to PERK because one study indicated that 
ATF4 stability is responsible for the induction of autophagy. Arrows indicate induction and crossed lines indicate repression. Dashed 
line indicate hypothesized, not proven, mechanism of Beclin 1 fragment induction of apoptosis. Large open arrow indicates that all 
three components contribute to CHOP induction
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biosynthetic intermediates appears to co-ordinate with 
macroautophagy through negative feedback of the 
TCA substrate, pyruvate, on macroautophagy [81]. Al-
though not specific for macroautophagy, staining with 
lysomotropic agents, such as acridine orange, is an ac-
ceptable marker for induction of macroautophagy [91]. 
Electron micrograph evidence of double-membraned 
vesicles containing cytoplasmic components is a gold 
standard for the presence of autophagosomes inside 
cells, while cleared vesicles provide evidence that the 
autophagic process is proceeding through to diges-
tion of the contents and not blocked by lysomotropic 
agents or other situations. An example of electron 
micrographic images of autophagosomes and cleared 
autophagolysomes induced in human ovarian cancer 
cells by treatment with a novel anti-cancer drug called 
SHetA2 (NSC 726189) is shown in Fig. 3.
INTEGRATION OF THE PROTEASOMAL 
SYSTEM AND AUTOPHAGY
The proteasome partners with autophagy to recycle 
cellular proteins by digesting single soluble proteins 
and releasing peptides into the cytoplasm and nucleus 
to be digested by peptidases, or to be transferred 
to the ER where they are bound by HLA (human leuko-
cyte antigen) proteins and eventually presented on the 
surface of the cell [25, 64]. Proteasomes are multi-
protein complexes made up of an inner 20S cylindri-
cal shaped core of subunits that have the proteolytic 
activity and a 19S regulatory cap of subunits on each 
end of the core which recognize ubiquitin-conjugated 
proteins and provide ATPase activity [36]. The protea-
some degrades type I (short-lived) and type II (mal-
folded/dysfunctional) proteins, whereas autophagy 
degrades type II and type III (long-lived) proteins [14]. 
The cellular ubiquitination system specifies 
whether a protein will be transferred to the protea-
some or an autophagosome for recycling. Proteins 
with attached polyubiquitin chains that are branched 
on Lys48 have a more closed conformation and are 
targeted for proteasomal degradation, while proteins 
with single ubiquitin moieties or polyubiquitin chains 
that are branched on other Lys residues are targeted 
to the autophagosomes as described above [98, 
121]. Some proteins can be digested by both the 
proteasome and autophagic vesicles [64]. Degrada-
tion of the proteins via the proteasome or autophagy 
is ultimately determined through competition for bind-
ing by adapter proteins, p62 and NBR, which shuttle 
the proteins to autophagic vesicles, or to p97, which 
shuttles the proteins to the proteasome [98, 125]. The 
p62 protein has a higher affinity for the monoubiquiti-
nated and Lys63 polyubiquitinated proteins targeted 
for autophagic degradation, but can also recognize 
Lys48 polyubiquitin chains targeted for proteasomal 
degradation, suggesting that p62 can compensate for 
loss of proteasomal function by bringing Lys48 ubiq-
uitylated proteins to the autophagosome when these 
proteins accumulate during proteasome overload 
or disfunction [40, 121]. 
There are several additional levels at which the pro-
teasome and autophagy are integrated. Inhibition of the 
proteasome leads to induction of autophagy [25–27], 
and induction of autophagy can protect cells from 
death induced by proteasomal inhibitors [52]. On the 
other hand, the proteasomal degradation pathway 
does not appear to compensate for loss of autophagy. 
Inhibition of early stages of autophagy results in buildup 
of the p62 adapter, which brings proteins, which would 
normally be degraded by the proteasome, instead 
to be accumulated in aggresomes where they can-
not be accessed by the proteasomal machinery [63]. 
Inhibition of autophagy at that last stage of lysosomal 
degradation by CQ, which does not cause aggresome 
accumulation, but instead allows the buildup of the 
ubiquitinated proteins inside lysosomal compartments, 
also is not compensated by proteasome activity [11]. 
This unequal relationship between autophagy and pro-
teasomal degradation is highlighted by the observations 
of proteasomes inside closed autophagic vesicles [21]. 
The induction of autophagy in response to proteasome 
inhibition is mediated through the unfolded protein 
response (UPR), which is induced when proteasomal 
inhibitors cause accumulation of polyubiquitinated 
proteins leading to ER stress (Fig. 2) [52]. 
INTEGRATION OF AUTOPHAGY WITH 
ER STRESS AND UPR
ER stress is caused by buildup of unfolded, mis-
folded or damaged proteins that exceeds the capacity 
of chaperones available in the ER to fold them. The UPR 
sets off a series of events that mitigate this stress and 
can also lead to induction of autophagy. The observa-
tion of ER stress, indicated by swollen ER, occurring 
in the same cell as autophagic vesicles upon treatment 
with the SHetA2 anticancer drug, but not upon treat-
ment with solvent only, supports the interconnection 
of these two processes (Fig. 3). An excess of unfolded/
misfolded proteins interferes with the repressive effect 
of the ER-resident chaperone, Grp78 (glucose regu-
lated protein 78, also called HSPA5 [heat shock protein 
A5] or BiP [Binding immunoglobulin protein]) on three 
UPR-regulatory proteins called PERK (double-stranded 
RNA-dependent protein kinase (PKR)-like ER kinase), 
IRE1α (inositol-requiring enzyme 1α) and ATF6 (Activat-
ing transcription factor 6) [93] (Fig. 2). Once released, 
PERK, IRE1α and ATF6 work in concert to mediate the 
UPR survival response involving arrest of general pro-
tein synthesis, while selected synthesis of chaperone 
proteins is allowed to continue in order to restore the 
balance of unfolded proteins/chaperones needed for 
ER homeostasis [43]. To further reduce the ER load, 
UPR can cause retrograde translocation of ER proteins 
to the cytoplasm where they are degraded in the pro-
teasome through ERAD (ER associated degradation) 
[84]. In situations of excess, irreparable or prolonged 
stress, UPR can transition into apoptosis by upregula-
tion of CHOP (CCAAT/-enhancer- binding protein ho-
mologous protein) and downstream GADD34 (Growth 
arrest and DNA damage 34), but in some situations 
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autophagy can intervene and prevent cell death by re-
moving the accumulated polyubiquitinated proteins and 
aggregates [29, 90]. 
ER stress induces autophagy directly through 
upregulation of Grp78 and through mechanisms 
downstream of Grp78 release of the three UPR 
signal transducers (Table 1, Fig. 2). A critical role 
for Grp78 in the induction of autophagy was de-
monstrated with knockdown of Grp78 in normal 
and cancer cells, which prevented autophagosome 
formation in response to starvation or in response 
to inhibition of protein processing with tunicamycin, 
an inhibitor of N-linked glycosylation [74]. This study 
also provided evidence for an integral co-dependency 
of intact ER and autophagy. The massively dilated and 
disrupted ER and the deficient autophagosome forma-
tion induced by Grp78 knockdown were both alleviated 
by simultaneous knockdown of the XBP-1 transcription 
factor, a downstream UPR mediator of IRE1α action 
required for ER expansion [71], suggesting that intact 
ER is maintained by and/or required for autophagy. The 
link between Grp78 and autophagy induction occurs 
downstream of nucleation, as the Grp78 knockdown 
had no effect on Beclin 1/Vps34 association.
The link between the IRE1α arm and upregulation 
of autophagy is mediated by IRE1α activation of JNK 
(c-Jun N terminal kinase). Proteasomal inhibition 
with bortezomib or MG132 induced ER stress and 
autophagy in colon cancer cells, but not in the pres-
ence of siRNA reduction of IRE1α or chemical inhibition 
of JNK activity, or in IRE1α knockout MEFs (murine em-
bryonic fibroblasts) [29]. In this study, the JNK inhibitor 
had no effect on XBP-1 activation and was equally ef-
fective in XBP-1-positive and -negative cells indicating 
that the UPR induction of autophagy occurs through 
JNK and not the IRE1α arm of UPR. As discussed 
above however, the XBP-1 function may be required 
to maintain the ER in a functional state to support au-
tophagic vesicle formation. A similar study conducted 
in neuroblastoma cells using specific siRNA knock-
down of IRE1α, PERK or ATF6, or using a JNK inhibitor, 
demonstrated that ER stress up-regulated autophagy 
through a mechanism dependent on IRE1α activation 
of JNK, but independently of PERK and ATF6 [90]. 
The ER stress was induced with tunicamycin or thap-
sigargin, a chemical that blocks ER calcium uptake 
by inhibiting ER Ca2+/ATPase. In this model, autophagy 
protected against cell death as demonstrated by the 
increase in cell death when autophagy was inhibited 
by chemical (3-MA [3-methyladenine]) or genetic 
manipulation (ATG7 siRNA), and inhibited cell death 
when autophagy was induced by chemical stimulation 
(rapamycin). The mechanism of autophagy induction 
downstream of JNK appears to be a result of JNK phos-
phorylation of Bcl-2, which releases Bcl-2 repression 
of Beclin mediation of autophagy [116].
Table 1. Mechanisms of ER stress and UPR induction of autophagy
Stressor Cell type Mechanism of autophagy upregulation R
Grp78:
Tunicamycin, 
Starvation
Embryonal kidney, 
cervical cancer
Downstream of nucleation 
(Vps34/Beclin1)
[74]
IRE1α Arm:
Bortezomib, 
MG132
Colon cancer, 
Prostate cancer
IRE1α → JNK → LC3B lipi-
dation
[29]
Tunicamycin,
Thapsigargin
Neuroblastoma IRE1α → JNK → LC3B lipida-
tion → autophagosomes 
[90]
PERK Arm:
Misfolded poly-
glutamine re-
peats
Embryonal carci-
noma
PERK phosphorylation → 
eIF2α phosphorylation → 
LC3 lipidation (possibly through 
increased ATF12 transcription)
[65]
Bortezomib Pancreatic cancer PERK phosphorylation → 
eIF2α phosphorylation → 
ATF4 → Atg 5 and Atg 7 trans-
cription
[129]
Bortezomib Breast cancer Reduction of proteasomal 
degradation of ATF4 → LC3B 
transcription
[85]
PERK, IRE1 α and ATF6 Arms:
SPP1 depletion Breast cancer ↑Grp78→ PERK+ IRE1α 
+ATF6 → LC3B lipidation
[72]
Indirect:
BrefeldinA, 
Thapsigargin, 
Tunicamycin
Gingival fibroblast p38MAPK → ↑Grp78 and 
↑Beclin1 and autophagic ves-
icles (possibly through p38 in-
hibition of mTORC1)
[55]
R = reference
Fig. 3. Simultaneous induction of ER stress and autophagy. Electron micrographs (X3250 magnification) of the human SK-OV-3 ovar-
ian cancer cell line treated with the SHetA2 anti-cancer drug (NSC 721689) for 17 hrs demonstrate normal nuclei (n) swollen ER 
(SER) and normal ER, double-membraned autophagic vessicles (A) and autophagolysosomes (AL) cleared of their contents, while 
control cells treated with the same volume of vehicle (dimethylsulfoxide) for 17 hrs do not exhibit SER, A or AL. The lack of clearly 
identified mitochondria (M) in the treated cells suggests that they may have been digested by autophagy. The inset is enlarged 
to show the double-membrane on an autophagosome
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The link between the PERK arm and upregulation 
of autophagy is ultimately mediated by ATF4-driven 
transcriptional upregulation of the ATG genes. Treat-
ment of embryonal carcinoma cells with misfolded 
polyglutamine repeats caused buildup of polyubiq-
uitinated protein aggregates and induced LC3 lipi-
dation through a mechanism dependent on PERK 
phosphorylation and activation of eIF2α, and result-
ing in autophagic elimination of the aggregates [65]. 
When the proteasomal inhibitor bortezomib was 
used in pancreatic cancer cells, the eIF2α led to ac-
tivation of ATF4-driven transcription of the ATG5 and 
ATG7 genes [129]. Activation of eIF2α also was shown 
to mediate induction of autophagy by starvation and 
viral infection [110]. Bortezomib treatment of breast 
cancer cells led to reduction of proteasomal degrada-
tion of ATF4, thereby increasing ATF4-mediated LC3B 
gene transcription [85].
All three of the UPR arms appear to be involved 
in the induction of autophagy in breast cancer cells 
caused by accumulation of the sphingolipid metabolite 
S1P (sphingosine-1-phosphate) phosphatase [72]. 
In this study, S1P levels were increased by siRNA si-
lencing of the SPP1 (S1P phosphatase) responsible 
for degradation of S1P in the ER. The resulting induc-
tion of autophagy was prevented by siRNA silencing 
of PERK, IRE1α, or ATF6 or a dominant negative 
PERK mutant. Other upstream inducers of Grp78 and 
autophagy that have not been characterized for spe-
cific UPR arm involvement in the mechanism include 
p38MAPK (p38 mitogen-activated protein kinase), 
which likely induces autophagy through inhibition 
of mTORC1 [55].
The ability of cellular UPR and autophagy respons-
es to ER stress to sufficiently mitigate the stress and 
allow survival is dependent upon the transformation 
state of the cell and the degree of stress. Although 
autophagy was induced in both cancer and non-trans-
formed cell lines by ER stress inducers tunicamycin, 
thapsigargin, A23187 (calcium ionophore) or brefeldin 
A (protein transport inhibitor) and could reduce the 
buildup of polyubiquitinated proteins, suppression 
of autophagy using chemical (3-MA) or genetic manip-
ulation (siRNA to Beclin 1 or LC3B) reduced cell death 
in colon and prostate cancer cell lines, but increased 
cell death in normal non-transformed fibroblast and 
non-immortalized human colon cell line [28]. The au-
thors of this study theorize that the macroautophagy 
in non-cancer cells may lead to cell death by digest-
ing normal by-stander cellular constituents needed 
for survival. Cancer cells characteristically become 
growth-independent of these survival factors. 
The switch between autophagy mediation of cell 
survival versus death has been shown to be related 
to the level of stress induced. In normal rat kidney cells, 
autophagy induced in response to a low dose of cis-
platin was required for cell survival, while autophagy 
induced in response to a high dose of cisplatin was 
required for cell death [103]. ER stress and Grp78 ap-
pear to mediate the induction of autophagy in this 
model. In a study of ER stress inducers (thapsigargin 
and tunicamycin) in murine embryonal fibroblasts, low, 
sublethal doses induced Grp78 expression and acti-
vated PERK, IRE1α and ATF6α [104]. Although CHOP 
was also induced, the upregulation was lost within 
24 hrs. Even when CHOP expression was persistently 
up-regulated, only expression of the down-stream 
GADD34 correlated with cell death. The authors of this 
study conclude that differential stability of the Grp78, 
CHOP and GADD34 mRNA’s and proteins contribute 
to the ultimate fate of the cell.
Similar to the addiction of some cancer cells to cer-
tain oncogenes, cancer cells may become dependent 
upon certain aspects of macroautophagy for cell sur-
vival and tumor growth, while defects in macroautoph-
agy that accumulate during tumor progression may 
allow adaptations that prevent apoptosis despite the 
presence of damaged proteins and organelles [118]. 
Consistent with this postulate, autophagy has been 
shown to be critical for K-ras transformation of breast 
cells [58]. In this model, K-ras induced transformation 
through a mechanism involving ROS (reactive oxygen 
species) induction of JNK. As discussed below, inhib-
iting autophagy is a current strategy in clinical trials 
to enhance chemotherapeutic response and overcome 
resistance of cancer cells.
AUTOPHAGY INTEGRATION WITH 
APOPTOSIS
Macroautophagy has been reported to play a role 
in cell death independently of apoptosis, but it remains 
unclear if this is a consequence of the severity and/
or extended duration of autophagy, or as a deliberate 
mechanism of programmed cell death. Autophagic 
cell death is often described as cell death in the ab-
sence of apoptotic caspase activation and presence 
of autophagic vesicles, but there lacks mechanism that 
clearly defines autophagic cell death [37]. Whether 
autophagy contributes to, or reduces, apoptosis 
in cancer cells is dependent upon the type of cell 
and the type and duration of stimulus. For instance, 
autophagy can act as a either a survival or death 
mechanism within the human SK-OV-3 ovarian cancer 
cell line, depending on the molecule used to treat the 
cells [62, 70, 128]. Also, loss of autophagy promotes 
or prevents fibroblast apoptosis depending on the 
death stimulus [115]. In the majority of oncology stud-
ies however, autophagy appears to play a protective 
role. For example, in multiple myeloma cells, genetic 
and chemical inhibition of autophagy enhances induc-
tion of apoptosis in vitro and tumor growth inhibition 
by DNA-damaging drugs, doxorubicin and melphalan 
in vivo [92]. In rat C6 glioma cells, siRNA silencing 
of ATG5, ATG7 or ULK1 genes increased apopto-
sis caused by cyclosporine A [16]. A recent study 
screened over 1400 cytotoxic agents for their ability 
to induce autophagic cell death in the U2Os osteosar-
coma cell line [107]. Of the 59 compounds that were 
validated to truly induce autophagic flux, none of them 
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were prevented from inducing cell death when the 
ATG7 gene critical for autophagy was knocked out.
Some fragments of the autophagic machinery 
are directly involved in the induction of apoptotic cell 
death through the intrinsic mitochondrial pathway. The 
transition to apoptosis appears to occur after autopha-
gy has been working to save the cell, but activation 
of specific proteases cleave Atg5 or Beclin 1 releas-
ing cleavage products that translocate to the mito-
chondria and induce the intrinsic apoptosis pathway 
(Fig. 2). This direct involvement of Atg5 in apoptosis 
was demonstrated by enhanced sensitivity of multiple 
cancer cell types to several cytotoxic chemotherapeu-
tic agents upon increased expression of Atg5 protein 
in vitro and in vivo, while silencing of the ATG5 gene had 
the opposite effect [127]. In this study, the switch from 
macroautophagy to apoptosis was mediated by cal-
pain cleavage of the Atg5 protein, releasing a truncated 
Atg5 that translocated to the mitochondria where 
it bound the anti-apoptotic Bcl-2 molecule, BclXL, 
thereby relieving BclXL inhibition of the BAX/BAK pore 
forming ability resulting in cytochrome c release from 
the mitochondria and caspase activation of apoptosis 
[127]. The Bcl-2 family of proteins also integrates mac-
roautophagy and apoptosis through Beclin 1. Under 
non-stressed conditions, Bcl-2 binds and sequesters 
Beclin 1 resulting in suppression of autophagosome 
formation [94]. Under stressed conditions, JNK be-
comes activated and phosphorylates Bcl-2, leading 
to Bcl-2 degradation and release of Beclin 1 to allow 
macroautophagy to attempt to recover cellular homeo-
stasis [116, 117]. Transition to apoptosis occurs when 
caspase 3 is activated resulting in a Beclin 1 C-terminal 
cleavage product that translocates to the mitochondria 
and enhances apoptosis by releasing pro-apoptotic 
factors [31, 120]. The known binding of Beclin 1 to the 
anti-apoptotic BclXL protein is a possible explanation 
for the induction of apoptosis, similar to what has been 
reported for Atg5 [88].
Another level of integration between autophagy and 
apoptosis is controlled by HMGB1 (high mobility group 
box 1), a nonhistone DNA-binding protein that binds 
tightly to chromatin of apoptotic cells and is released 
from necrotic cells [2]. In response to autophagic 
stimuli, HMGB1 translocates from the nucleus to the 
cytosol where it binds directly to Beclin 1 causing the 
release of Bcl-2 and allowing Beclin 1 to increase au-
tophagy [111]. Much less is known about the integra-
tion of autophagy and programmed necrosis. Although 
autophagic vesicles have been observed in necrotic 
cells [2], it is not clear if autophagy is contributing 
to the cell death in this situation. Based on the ob-
servation that combined inhibition of autophagy and 
apoptosis stimulates necrosis in cancer cells exposed 
to ischemic conditions, autophagy appears to prevent 
necrosis [24].
Inconsistent ordering of autophagy and UPR events 
reported to occur prior to apoptosis suggest that the 
transition from cell survival to apoptotic death is not 
linear, but instead driven by an integrated network 
of events that can eventually tip the balance to sur-
vival or death. For example, JNK can be activated 
upstream of macroautophagy by ER stress, but can 
also be activated downstream of macroautophagy 
by etoposide or staurosporine treatment of apoptosis-
deficient MEFs [108]. This inconsistency suggests that 
the pathways are not connected in a linear sequence, 
but instead integrated at multiple levels. A simplified 
interpretation may be that autophagic cell death is not 
a mechanism designed by the cell, but rather a rare 
consequence of too much autophagy in response 
to external stimuli, such as chemical reagents or pro-
longed stress. The unrestrained autophagy could lead 
to cell death in the absence of apoptosis by consum-
ing the viable cell mass or by upsetting the balance 
of pro-survival versus pro-apoptotic proteins. This may 
explain why a definitive molecular mechanism for pro-
grammed autophagic cell death has not been defined.
TARGETING MACROAUTOPHAGY 
IN CANCER THERAPY
While there is evidence that macroautophagy can 
suppress the early development of cancer [13], upreg-
ulation of basal levels of autophagy in multiple cancers 
indicate that autophagy primarily drives survival once 
the tumor has formed [33]. A recently developed meth-
od to detect macroautophagy in clinical specimens 
using immunohistochemistry with an antibody to LC3B 
demonstrated that punctuate pattern staining of LC3B 
indicative of macroautophagy significantly correlated 
with heightened cell proliferation and nuclear grade, 
invasion and metastasis, and worse outcome [69]. 
This is of particular significance because multiple anti-
cancer agents are known to induce macroautophagy, 
which could interfere with tumor response (Table 2). 
Table 2. Anti-cancer agents that induce autophagy
Function Name R
Alkylating agents Cyclophosphamide, Temozolomide [3, 50]
Bcl2 inhibitor GX15-070 [47]*
Farnesyltransferase in-
hibitor
Lonafarnib [47]*
Glycolysis inhibitors GX15-070, 2-deoxyglucose [47]*
HDAC inhibitors Vorinostat, Sodium butyrate, LAQ824, 
Panobinostat
[47]*
Hormone treatments Tamoxifen,Toremifene [47]*
Ionizing radiation Cs-137 [91,124]
Microtubule inhibitor Vinblastine [101]
Monoclonal antibodies Rituximab (to CD20), Panitumumab 
(to EGF-R)
[47]*
mTOR inhibitors Sirolimus, Temsirolimus, Everolimus, 
NV-128
[47]*
Natural compounds Arsenic, resveratrol [47]*
PARP inhibitor ABT-888 [47]*
Proteasome inhibitors Bortezomib, NPI-0052114, Epoxomicin [47]*
Topoisomerase poisons Doxorubicin, Campothecin [73, 78]
Tyrosine kinase inhibitors Dasatinib, Sorafenib, Imatinib [47]*
Vitamin D analog EB1089 [47]*
R = references, * Multiple references are provided in this review.
Preclinical studies demonstrating a protective role 
for macroautophagy in response to these therapeutics 
have translated into multiple clinical trials evalua ting 
CQ and the derivative HCQ (hydroxychloroquine) 
inhibition of autophagy in combination with a variety 
of current cancer treatment strategies. CQ and HCQ 
are “old drugs” that have been prescribed for malaria 
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[89], rheumatoid arthritis [66] and HIV [102]. The first 
reported clinical trial of combining autophagy inhibition 
with cancer therapy was a single-institution phase III 
trial in glioblastoma patients treated with conventional 
radiation and carmustine therapy with or without daily 
CQ [109]. Although this study was not adequately 
powered to detect a significant difference in survival, 
CQ increased overall survival from 11 months in the 
placebo arm to 24 months in the CQ arm. HCQ is a less 
toxic version of CQ and the best autophagy inhibitor 
currently commercially available for clinical trials [39]. 
Currently there are 84 clinical trials of HCQ listed on the 
United States Government website (ClinicalTrials.gov), 
of which 33 are cancer studies, including 15 Phase I, 
nine Phase I/II, and nine Phase II clinical trials of HCQ 
in combination with a range of chemotherapeutic 
agents.
In contrast to the sensitization of tumors to che-
motherapeutic agents by autophagy inhibition, the 
sensitivity of tumors to radiation has been shown 
to be enhanced by induction of autophagy with the 
mTOR inhibitor everolimus (RAD001) and further 
enhanced by combined inhibition of apoptosis and 
induction of autophagy [9, 57]. There are several early 
phase clinical trials of everolimus or rapamycin in com-
bination with radiation therapy for a variety of cancers 
listed on the ClinicalTrials.gov website. The translation 
of laboratory-based autophagy studies to clinical trials 
is based primarily on research of macroautophagy, 
however there is considerable integration of mac-
roautophagy with the other forms of autophagy that 
could be taken advantage of in this cancer treatment 
strategy, and that needs to be taken into consideration 
to fully understand the impact of the interventions and 
the interpretation of results.
MECHANISM AND INTEGRATION 
OF CHAPERONE-MEDIATED AUTOPHAGY
CMA involves the selective degradation of indi-
vidual molecules containing an amino acid sequence 
motif related to KFERQ (Lys-Phe-Glu-Arg-Gln) [27]. 
CMA activity can be measured in cells by the transition 
of diffuse to punctuate pattern of a photoconvertible 
KFERQ-PA-mCherryl reporter protein in transfected 
cells [61]. It is estimated that at least 30% of cytosolic 
proteins contain this sequence or a sequence that can 
be made mimic KFERQ through post-translational 
modifications [26]. The proteins may have KFERQ lo-
cated on their surface for recognition by Hsc70 or this 
sequence may become exposed upon damage or de-
naturing of the protein, or upon separation of the pro-
tein with another protein subunit. A single molecular 
chaperone (Hsc70/HSPA8) appears to mediate the 
recognition of proteins with exposed KFERQ domains 
and transporting them to the lysosome [15]. At the 
lysosome, Hsc70 binds LAMP-2A (Lysosome-asso-
ciated membrane protein type 2A), and interacts with 
a complex of other chaperones to unfold the trans-
ported protein and push it through LAMP-2A to an-
other molecule of Hsc70 waiting inside the lysosome 
[1]. Increased expression of LAMP2A and lysosomal 
Hsc70 correlate with CMA activity and are accepted 
markers of CMA [18, 19]. Hsc70 binds and hydrolyzes 
ATP in order to generate the energy required for this 
process, and the ADP-bound form of Hsc70 has the 
highest affinity for KFERQ proteins [48]. The proteins 
working with Hsc70 at the surface of the lysosome 
have unique functions. Hsp40 activates Hsc70 ATPase 
activity to increase affinity for protein substrates, Hip 
(heat shock protein 70 interacting protein) facilitates 
the assembly of the various proteins in the complex, 
cdc48 (cell division cycle 48) stimulates the activity 
of this protein complex, and Bag-1 (Bcl-2-associated 
athanogene 1) acts as a nucleotide exchange factor 
that stimulates substrate release [76]. The stability 
of Hsc70 inside the lysosome is tightly controlled by the 
pH of the lumen, which, if altered, could denature 
Hsc70 and make it susceptible to lysosomal proteases 
[19]. LAMP-2A also works as a complex with EF1α 
(elongation factor 1 α) to form a complex with GFAP 
(glial fibrillary acidic protein) that can be negatively 
regulated by GTP, which causes dissociation of the 
complex subunits [5].
CMA is a second line response to cell starvation [7]. 
Macroautophagy is the first line response to nutrient 
deprivation with maximal activity around 6 hours, fol-
lowed by a gradual reduction [35, 83]. There appears 
to be mutual inhibition between macroautophagy and 
CMA, as CMA does not increase to suprabasal levels 
until the reduction of macroautophagy 6 to 8 hours 
after initiation of starvation [7]. Maximal CMA occurs 
24 hours after initiation of starvation and continues 
for at least 3 days [20]. Although inhibition of macro-
autophagy or CMA can lead to upregulation of each 
other, the compensation is incomplete, as CMA cannot 
degrade organelles and macroautophagy cannot com-
pensate for the selectivity of CMA. Inhibition of CMA 
by blocking expression of LAMP-2A in fibroblasts 
resulted in increased macroautophagy, however this 
compensatory action did not alleviate the increased 
sensitivity of CMA-deficient cells to stress [83]. In-
hibition of macroautophagy with type III PI3K inhibi-
tors (3-3-MA, wortmannin or LY294002) or activation 
of macroautophagy with rapamycin, had no effect 
on CMA [35], however macroautophagy-deficient 
cells caused by genetic deletion of ATG5 exhibit up-
regulation of both basal and induced CMA through 
different mechanisms [51]. Although there is little 
evidence to document direct integration of CMA with 
ER stress or UPR, integration of CMA with proteasomal 
degradation is indicated by the selective degradation 
of proteasomal catalytic core subunits by CMA [21]. 
Deregulated CMA has been shown to cause mul-
tiple diseases including MLIV (mucolipidosis Type 
IV), which is caused by defects in TRPML1 (transient 
receptor potential mucolipin-1) leading to ineffec-
tive docking with Hsc70 inside the lysosome [114], 
glaucoma and other diseases related to ineffective 
Hsc70 transport of proteins along neuronal axons [39]. 
In cancer, levels of the MDM2 (murine double minute 
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2) regulator of the p53 tumor suppressor protein and 
the Gal3 (Galectin-3) oncogenic protein, and likely 
multiple other oncongenes and tumor suppressor 
genes, are controlled by CMA [77, 80]. A recent study 
demonstrated that inhibition of constitutively upregu-
lated CMA by silencing Lamp-2A expression caused 
increased p53 levels resulting in reduced proliferation 
and altered metabolism in human lung cancer cells 
in vitro and reduced tumor growth and metastases 
in vivo, indicating that CMA is a relevant target for 
anti-cancer therapy [61].
MICROAUTOPHAGY
Although microautophagy was originally described 
by de Duve and Wattiauz in 1963, the term was not 
coined until 1983 [23]. While much less well chara-
cterized than macroautophagy and CMA, studies 
of microautophagy have led to the delineation of 5 se-
quential steps that mediate microautophagy, namely: 
invagination, vesicle formation, vesicle expansion, 
vesicle scission and vesicle degradation and recycling 
[75]. The first step of invagination is an ATP-depen-
dent process that occurs at areas of the lysosomal 
membrane with low concentrations of transmem-
brane proteins and that develops as tubes filled with 
cytoplasmic components, in contrast to the shapes 
of other types of lysosomal invaginations [82, 106]. 
The subsequent processes are mediated by mTOR 
regulated ubiquitin-like systems, LC3 lipidation and 
other Atg machinery similar to that discussed above 
for macroautophagy [75]. Selective microautophagy 
degradation of mitochondria (micromitophagy), the 
nucleus (PMN [piecemeal microautophagy of the nu-
cleus]) and peroxisomes (micropexophagy) have been 
described [34, 54, 67]. Similar to macroautophagy 
and CMA, microautophagy occurs at basal levels and 
can be induced by nitrogen starvation or mitochon-
drial damage, however in contrast to the antagonism 
of macroautophagy with CMA, microautophagy ap-
pears to work synergistically with the other two forms 
of autophagy [17]. Although primarily characterized 
in yeast, defects in microautophagy have been linked 
to a number of human diseases, however a direct link 
with cancer has not been identified [75].
CONCLUSIONS
Are current definitions of pathways and modes 
of cell stress response, survival and death limiting our 
ability to comprehend the dynamic cell? Models are 
useful, but can introduce bias into our comprehension. 
This review has described multiple levels of integration 
between various pathways that can maintain cellular 
homeostasis or default into apoptosis. Upon stress 
to the system, the ultimate consequence of cell sur-
vival or death depends on balance of events linked 
at multiple network connections, similar to a hanging 
mobile. In this model, failure to balance the weights 
of proteasomal degradation, UPR and autophagy 
against apoptosis and other forms of cell death, such 
as programmed necrosis, can lead to excessive au-
tophagy consuming the viable cell mass or to the relief 
of inhibition of the default apoptosis pathway that is al-
ways present and waiting for relief of inhibition to kill 
the cell. The detailed molecular interactions described 
in this review provide information on the nodes of this 
complex network that can be manipulated to control 
the network in development of strategies to induce 
apoptosis in cancer cells without harming normal cells.
REFERENCES
1. Agarraberes FA, Terlecky SR, Dice JF. An intralyso-
somal hsp70 is required for a selective pathway of lysosomal 
protein degradation. J Cell Biol 1997; 137: 825–34.
2. Amaravadi RK, Thompson CB. The roles of therapy-
induced autophagy and necrosis in cancer treatment. Clin 
Cancer Res 2007; 13: 7271–9.
3. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibi-
tion enhances therapy-induced apoptosis in a Myc-induced 
model of lymphoma. J Clin Invest 2007; 117: 326–36.
4. Avruch J, Hara K, Lin Y, et al. Insulin and amino-acid 
regulation of mTOR signaling and kinase activity through the 
Rheb GTPase. Oncogene 2006; 25: 6361–72.
5. Bandyopadhyay U, Sridhar S, Kaushik S, et al. Identi-
fication of regulators of chaperone-mediated autophagy. Mol 
Cell 2010; 39: 535–47.
6. Barth S, Glick D, Macleod KF. Autophagy: assays and 
artifacts. J Pathol 2010; 221: 117–24.
7. Bejarano E, Cuervo AM. Chaperone-mediated au-
tophagy. Proc Am Thorac Soc 2010; 7: 29–39.
8. Benbrook DM, Masamha CP. The pro-survival function 
of Akt kinase can be overridden or altered to contribute to induc-
tion of apoptosis. Curr Cancer Drug Targets 2011; 11: 586–99.
9. Cao C, Subhawong T, Albert JM, et al. Inhibition 
of mammalian target of rapamycin or apoptotic pathway 
induces autophagy and radiosensitizes PTEN null prostate 
cancer cells. Cancer Res 2006; 66: 10040–7.
10. Carew J, Kelly K, Nawrocki S. Mechanisms of mTOR in-
hibitor resistance in cancer therapy. Target Oncol 2011; 6: 17–27.
11. Carew JS, Medina EC, Esquivel JA 2nd, et al. Autophagy 
inhibition enhances vorinostat-induced apoptosis via ubiquiti-
nated protein accumulation. J Cell Mol Med 2010; 14: 2448–59.
12. Chan EY. mTORC1 phosphorylates the ULK1-mAtg13-
FIP200 autophagy regulatory complex. Sci Signal 2009; 2: pe51.
13. Chen N, Karantza-Wadsworth V. Role and regula-
tion of autophagy in cancer. Biochim Biophys Acta 2009; 
1793: 1516–23.
14. Chen X, Yin XM. Coordination of autophagy and the 
proteasome in resolving endoplasmic reticulum stress. Vet 
Pathol 2011; 48: 245–53.
15. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for 
a 70-kilodalton heat shock protein in lysosomal degradation 
of intracellular proteins. Science 1989; 246: 382–5.
16. Ciechomska IA, Gabrusiewicz K, Szczepankiewicz AA, 
Kaminska B. Endoplasmic reticulum stress triggers autophagy 
in malignant glioma cells undergoing cyclosporine A-induced 
cell death. Oncogene 2012 [Epub ahead of print].
17. Cuervo AM. Autophagy: many paths to the same end. 
Mol Cell Biochem 2004; 263: 55–72.
18. Cuervo AM, Dice JF. Regulation of lamp2a levels in the 
lysosomal membrane. Traffic 2000; 1: 570–83.
19. Cuervo AM, Dice JF, Knecht E. A population of rat liver 
lysosomes responsible for the selective uptake and degradation 
of cytosolic proteins. J Biol Chem 1997; 272: 5606–15.
20. Cuervo AM, Knecht E, Terlecky SR, Dice JF. Activa-
tion of a selective pathway of lysosomal proteolysis in rat liver 
by prolonged starvation. Am J Physiol 1995; 269: C1200–8.
Experimental Oncology 34, 286–297, 2012 (September) 295
21. Cuervo AM, Palmer A, Rivett AJ, Knecht E. Degrada-
tion of proteasomes by lysosomes in rat liver. Eur J Biochem 
1995; 227: 792–800.
22. de Duve C. The lysosome. Sci Am 1963; 208: 64–72.
23. de Duve C, Wattiauz R. Function of lysosomes. Annu 
Rev Physiol 1966; 28: 435–92.
24. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy 
promotes tumor cell survival and restricts necrosis, inflamma-
tion, and tumorigenesis. Cancer Cell 2006; 10: 51–64.
25. Dengjel J, Schoor O, Fischer R, et al. Autophagy pro-
motes MHC class II presentation of peptides from intracellular 
source proteins. Proc Natl Acad Sci USA 2005; 102: 7922–7.
26. Dice JF. Chaperone-mediated autophagy. Autophagy 
2007; 3: 295–9.
27. Dice JF, Chiang HL, Spencer EP, Backer JM. Regula-
tion of catabolism of microinjected ribonuclease A. Identifi-
cation of residues 7–11 as the essential pentapeptide. J Biol 
Chem 1986; 257: 14624–7.
28. Ding W-X, Ni H-M, Gao W, et al. Differential effects 
of endoplasmic reticulum stress-induced autophagy on sell 
survival. J Biol Chem 2007; 282: 4702–10.
29. Ding W-X, Ni H-M, Gao W, et al. Linking of autophagy 
to ubiquitin-proteasome system is important for the regulation 
of endoplasmic reticulum stress and cell viability. Am J Pathol 
2007; 171: 513–24.
30. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Fer-
roptosis: an iron-dependent form of nonapoptotic cell death. 
Cell 2012; 149: 1060–72.
31. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross 
talk between apoptosis and autophagy by caspase-mediated 
cleavage of Beclin 1. Oncogene 2010; 29: 1717–9.
32. Eskelinen E-L. Maturation of autophagic vacuoles 
in mammalian cells. Autophagy 2005; 1: 1–10.
33. Espina V, Mariani BD, Gallagher RI, et al. Malignant 
precursor cells pre-exist in human breast DCIS and require 
autophagy for survival. PLoS One 2010; 5: e10240.
34. Farré J-C, Subramani S. Peroxisome turnover by mi-
cropexophagy: an autophagy-related process. Trends Cell Biol 
2004; 14: 515–23.
35. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small 
molecules on chaperone-mediated autophagy. Autophagy 
2005; 1: 141–5.
36. Frankland-Searby S, Bhaumik SR. The 26S protea-
some complex: an attractive target for cancer therapy. Biochim 
Biophys Acta 2012; 1825: 64–76.
37. Galluzzi L, Vitale I, Abrams JM, et al. Molecular 
definitions of cell death subroutines: recommendations of the 
Nomenclature Committee on Cell Death 2012. Cell Death 
Differ 2012; 19: 107–20.
38. Ganley IG, Lam du H, Wang J, et al. ULK1.ATG13.FIP200 com-
plex mediates mTOR signaling and is essential for autophagy. J Biol 
Chem 2009; 284: 12297–305.
39. Garber K. Inducing indigestion: companies embrace 
autophagy inhibitors. J Natl Cancer Inst 2011; 9: 708–10.
40. Geetha T, Seibenhener ML, Chen L, et al. p62 serves 
as a shuttling factor for TrkA interaction with the proteasome. 
Biochem Biophys Res Commun 2008; 374: 33–7.
41. Hailey DW, Rambold AS, Satpute-Krishnan P, et al. 
Mitochondria supply membranes for autophagosome biogen-
esis during starvation. Cell 2010; 141: 656–67.
42. Hayashi-Nishino M, Fujita N, Noda T, et al. A subdo-
main of the endoplasmic reticulum forms a cradle for autopha-
gosome formation. Nat Cell Biol 2009; 11: 1433–7.
43. Hetz C. The unfolded protein response: controlling 
cell fate decisions under ER stress and beyond. Nat Rev Mol 
Cell Biol 2012; 13: 89–102.
44. Hosokawa N, Hara T, Kaizuka T, et al. Nutrient-depen-
dent mTORC1 association with the ULK1-Atg13-FIP200 com-
plex required for autophagy. Mol Biol Cell 2009; 20: 1981–91.
45. Ichimura Y, Kirisako T, Takao T, et al. A ubiquitin-like 
system mediates protein lipidation. Nature 2000; 408: 488–92.
46. Inoki K, Kim J, Guan K-L. AMPK and mTOR in cellu-
lar energy homeostasis and drug targets. Annu Rev Pharmacol 
Toxicol 2012; 52: 381–400.
47. Janku F, McConkey DJ, Hong DS, Kurzrock R. Au-
tophagy as a target for anticancer therapy. Nat Rev Clin Oncol 
2011; 8: 528–39.
48. Jiang J, Prasad K, Lafer EM, Sousa R. Structural basis 
of interdomain communication in the Hsc70 chaperone. Mol 
Cell 2005; 20: 513–24.
49. Jung CH, Jun CB, Ro S-H, et al. ULK-Atg13-
FIP200 complexes mediate mTOR signaling to the autophagy 
machinery. Mol Biol Cell 2009; 20: 1992–2003.
50. Kanzawa T, Germano IM, Komata T, et al. Role of au-
tophagy in temozolomide-induced cytotoxicity for malignant 
glioma cells. Cell Death Differ 2004; 11: 448–57.
51. Kaushik S, Massey AC, Mizushima N, Cuer-
vo AM. Constitutive activation of chaperone-mediated 
autophagy in cells with impaired macroautophagy. Mol Biol 
Cell 2008; 19: 2179–92.
52. Kawaguchi T, Miyazawa K, Moriya S, et al. Combined 
treatment with bortezomib plus bafilomycin A1 enhances the 
cytocidal effect and induces endoplasmic reticulum stress 
in U266 myeloma cells: crosstalk among proteasome, autoph-
agy-lysosome and ER stress. Int J Oncol 2011; 38: 643–54.
53. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacety-
lase HDAC6 regulates aggresome formation and cell viability 
in response to misfolded protein stress. Cell 2003; 115: 727–38.
54. Kissová I, Salin B, Schaeffer J, et al. Selective and 
non-selective autophagic degradation of mitochondria in yeast. 
Autophagy 2007; 3: 329–36.
55. Kim D-S, Kim J-H, Lee G-H, et al. p38 Mitogen-
activated protein kinase is involved in endoplasmic reticulum 
stress-induced cell death and autophagy in human gingival 
fibroblasts. Biol Pharm Bull 2010; 33: 545–9.
56. Kim E, Goraksha-Hicks P, Li L, et al. Regulation 
of TORC1 by Rag GTPases in nutrient response. Nat Cell 
Biol 2008; 10: 935–45.
57. Kim KW, Hwang M, Moretti L, et al. Autophagy 
upregulation by inhibitors of caspase-3 and mTOR enhances 
radiotherapy in a mouse model of lung cancer. Autophagy 
2008; 4: 659–68.
58. Kim M-J, Woo S-J, Yoon C-H, et al. Involvement 
of autophagy in oncogenic K-Ras-induced malignant cell 
transformation. J Biol Chem 2011; 286: 12924–32.
59. Klionsky DJ. Autophagy revisited: A conversation with 
Christian de Duve. Autophagy 2008; 4: 740–3.
60. Klionsky DJ, Cregg JM, Dunn WA Jr, et al. A unified 
nomenclature for yeast autophagy-related genes. Dev Cell 
2003; 5: 539–45.
61. Kon M, Kiffin R, Koga H, et al. Chaperone-mediated 
autophagy is required for tumor growth. Sci Transl Med 2012; 
3: 109ra117.
62. Kong D, Ma S, Liang B, et al. The different regulatory 
effects of p53 status on multidrug resistance are determined 
by autophagy in ovarian cancer cells. Biomed Pharmacother 
2012; 66: 271–8.
63. Korolchuk VI, Mansilla A, Menzies FM, Rubinsz-
tein DC. Autophagy inhibition compromises degradation 
of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 
33: 517–27.
296 Experimental Oncology 34, 286–297, 2012 (September)
64. Korolchuk VI, Menzies FM, Rubinsztein DC. Mecha-
nisms of cross-talk between the ubiquitin-proteasome and 
autophagy-lysosome systems. FEBS Lett 2010; 584: 1393–8.
65. Kouroku Y, Fujita E, Tanida I, et al. ER stress (PERK/
eIF2 alpha phosphorylation) mediates the polyglutamine-
induced LC3 conversion, an essential step for autophagy 
formation. Cell Death Differ 2007; 14: 230–9.
66. Kremer JM. Rational use of new and existing disease-
modifying agents in rheumatoid arthritis. Ann Intern Med 
2001; 134: 695–706.
67. Krick R, Mühe Y, Prick T, et al. Piecemeal microau-
tophagy of the nucleus: Genetic and morphological traits. 
Autophagy 2009; 5: 270–2.
68. Kroemer G, Galluzzi L, Vandenabeele P, et al. and 
Nomenclature Committee on Cell Death. Classification of cell 
death: recommendations of the Nomenclature Committee 
on Cell Death 2009. Cell Death Differ 2009; 16: 3–11.
69. Lazova R, Camp RL, Klump V, et al. Punctate LC3B 
expression is a common feature of solid tumors and associated 
with proliferation, metastasis, and poor outcome. Clin Cancer 
Res 2012; 18: 370–9.
70. Le X-F, Mao W, Lu Z, et al. Dasatinib induces au-
tophagic cell death in human ovarian cancer. Cancer 2010; 
116: 4980–90.
71. Lee AH, Chu GC, Iwakoshi NN, Glim cher LH. XBP-1 is re-
quired for biogenesis of cellular secretory machinery of exocrine 
glands. EMBO J 2005; 24: 4368–80.
72. Lepine S, Allegood JC, Park M, et al. Sphingosine-
1-phosphate phosphohydrolase-1 regulates ER stress-induced 
autophagy. Cell Death Differ 2011; 18: 350–61.
73. Li H, Wang P, Sun Q, et al. Following cytochrome 
c release, autophagy is inhibited during chemotherapy-induced 
apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer 
Res 2011; 71: 3625–34.
74. Li J, Ni M, Lee B, et al. The unfolded protein response 
regulator GRP78/BiP is required for endoplasmic reticulum 
integrity and stress-induced autophagy in mammalian cells. 
Cell Death Differ 2008; 15: 1460–71.
75. Li WW, Li J, Bao JK. Microautophagy: lesser-known 
self-eating. Cell Mol Life Sci 2012; 69: 1125–36.
76. Li W, Yang Q, Mao Z. Chaperone-mediated auto-
phagy: machinery, regulation and biological consequences. 
Cell Mol Life Sci 2011; 68: 749–63.
77. Li X, Ma Q, Wang J, et al. c-Abl and Arg tyrosine 
kinases regulate lysosomal degradation of the oncoprotein 
Galectin-3. Cell Death Differ 2010; 17: 1277–87.
78. Lin C-I, Whang EE, Abramson MA, et al. Autopha-
gy: a new target for advanced papillary thyroid cancer therapy. 
Surgery 2009; 146: 1208–14.
79. Lindmo K, Stenmark H. Regulation of membrane traffic 
by phosphoinositide 3-kinases. J Cell Sci 2006; 119: 605–14.
80. Lu T-L, Huang G-J, Wang H-J, et al. Hispolon pro-
motes MDM2 downregulation through chaperone-mediated 
autophagy. Biochem Biophys Res Commun 2010; 398: 26–31.
81. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy 
in metazoans: cell survival in the land of plenty. Nat Rev Mol 
Cell Biol 2005; 6: 439–48.
82. Müller O, Sattler T, Flötenmeyer M, et al. Autophagic 
tubes. The J Cell Biol 2000; 151: 519–28.
83. Massey AC, Kaushik S, Sovak G, et al. Consequences 
of the selective blockage of chaperone-mediated autophagy. 
Proc Natl Acad Sci USA 2006; 103: 5805–10.
84. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the 
long road to destruction. Nat Cell Biol 2005; 7: 766–72.
85. Milani M, Rzymski T, Mellor HR, et al. The role 
of ATF4 stabilization and autophagy in resistance of breast 
cancer cells treated with Bortezomib. Cancer Res 2009; 
69: 4415–23.
86. Mizushima N, Yamamoto A, Hatano M, et al. Dissec-
tion of autophagosome formation using Apg5-deficient mouse 
embryonic stem cells. J Cell Biol 2001; 152: 657–68.
87. Nishida Y, Arakawa S, Fujitani K, et al. Discovery 
of Atg5/Atg7-independent alternative macroautophagy. Na-
ture 2009; 461: 654–8.
88. Noble CG, Dong J-M, Manser E, Song H. BclXL and 
UVRAG cause a monomer-dimer switch in Beclin1. J Biol 
Chem 2008; 283: 26274–82.
89. O’Neill PM, Bray PG, Hawley SR, et al. 4-Amino-
quinolines — Past, present, and future: A chemical perspective. 
Pharmacol Ther 1998; 77: 29–58.
90. Ogata M, Hino S, Saito A, et al. Autophagy is activated 
for cell survival after endoplasmic reticulum stress. Mol Cell 
Biol 2006; 26: 9220–31.
91. Paglin S, Hollister T, Delohery T, et al. A novel response 
of cancer cells to radiation involves autophagy and formation 
of acidic vesicles. Cancer Res 2001; 61: 439–44.
92. Pan Y, Gao Y, Chen L, et al. Targeting autophagy 
augments in vitro and in vivo antimyeloma activity of DNA-
damaging chemotherapy. Clin Cancer Res 2011; 17: 3248–58.
93. Parmar VM, Schroder M. Sensing endoplasmic reticu-
lum stress. Adv Exp Med Biol 2012; 738: 153–68.
94. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic 
proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 
122: 927–39.
95. Petiot A, Ogier-Denis E, Blommaart EF, et al. Distinct 
classes of phosphatidylinositol 3’-kinases are involved in sig-
naling pathways that control macroautophagy in HT-29 cells. 
J Biol Chem 2000; 275: 992–8.
96. Pickart CM. Mechanisms underlying ubiquitination. 
Ann Rev Biochem 2001; 70: 503–33.
97. Polson HE, de Lartigue J, Rigden DJ, et al. Mammalian 
Atg18 (WIPI2) localizes to omegasome-anchored phago phores and 
positively regulates LC3 lipidation. Autophagy 2010; 6: 506–22.
98. Popovic D, Dikic I. The molecular basis of selective 
autophagy. Biochemist 2012; 34: 24–30.
99. Ravikumar B, Acevedo-Arozena A, Imarisio S, et al. 
Dynein mutations impair autophagic clearance of aggregate-
prone proteins. Nat Genet 2005; 37: 771–6.
100. Ravikumar B, Moreau K, Jahreiss L, et al. Plasma 
membrane contributes to the formation of pre-autophago-
somal structures. Nat Cell Biol 2010; 12: 747–57.
101. Rez G, Csak J, Fellinger E, et al. Time course of vinblas-
tine-induced autophagocytosis and changes in the endoplasmic 
reticulum in murine pancreatic acinar cells: a morphometric and 
biochemical study. Eur J Cell Biol 1996; 71: 341–50.
102. Romanelli F, Smith KM, Hoven AD. Chloroquine and 
hydroxychloroquine as inhibitors of human immunodeficiency 
virus (HIV-1) activity Curr Pharm Des 2004; 10: 2643–8.
103. Rovetta F, Stacchiotti A, Consiglio A, et al. ER sig-
naling regulation drives the switch between autophagy and 
apoptosis in NRK-52E cells exposed to cisplatin. Exp Cell 
Res 2012; 318: 238–50.
104. Rutkowski DT, Arnold SM, Miller CN, et al. Adapta-
tion to ER stress is mediated by differential stabilities of pro-
survival and pro-apoptotic mRNAs and proteins. PLoS Biol 
2006; 4: e374.
105. Sancak Y, Peterson TR, Shaul YD, et al. The Rag 
GTPases bind Raptor and mediate amino acid signaling 
to mTORC1. Science 2008; 320: 1496–501.
106. Sattler T, Mayer A. Cell-free reconstitution of micro-
autophagic vacuole invagination and vesicle formation. J Cell 
Biol 2000; 151: 529–38.
Experimental Oncology 34, 286–297, 2012 (September) 297
107. Shen S, Kepp O, Michaud M, et al. Association and 
dissociation of autophagy, apoptosis and necrosis by systematic 
chemical study. Oncogene 2011; 30: 4544–56.
108. Shimizu S, Konishi A, Nishida Y, et al. Involvement 
of JNK in the regulation of autophagic cell death. Oncogene 
2010; 29: 2070–82.
109. Sotelo J, Briceño E, López-González MA. Adding 
chloroquine to conventional treatment for glioblastoma mul-
tiforme. Ann Intern Med 2006; 144: 337–43.
110. Tallóczy Z, Jiang W, Virgin HW 4th, et al. Regulation 
of starvation- and virus-induced autophagy by the eIF2alpha 
kinase signaling pathway. Proc Natl Acad Sci USA 2002; 
99: 190–5.
111. Tang D, Kang R, Livesey KM, et al. Endogenous 
HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881–92.
112. Tanida I. Autophagy basics. Microbiol Immunol 
2011; 55: 1–11.
113. Vance JE, Vance DE. Phospholipid biosynthesis 
in mammalian cells. Biochem Cell Biol 2004; 82: 113–28.
114. Venugopal B, Mesires NT, Kennedy JC, et al. Chape-
rone-mediated autophagy is defective in mucolipidosis type 
IV. J Cell Physiol 2009; 219: 344–53.
115. Wang Y, Singh R, Massey AC, et al. Loss of macroau-
tophagy promotes or prevents fibroblast apoptosis depending 
on the death stimulus. J Biol Chem 2008; 283: 4766–77.
116. Wei Y, Pattingre S, Sinha S, et al. JNK1-mediated 
phosphorylation of Bcl-2 regulates starvation-induced au-
tophagy. Mol Cell 2008; 30: 678–88.
117. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated 
phosphorylation of Bcl-2 in autophagy and apoptosis regula-
tion. Autophagy 2008; 4: 949–51.
118. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 
2008; 68: 3077–80.
119. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and 
ubiquitin-like proteins as multifunctional signals. Nat Rev Mol 
Cell Biol 2005; 6: 599–609.
120. Wirawan E, Vande Walle L, Kersse K, et al. Caspase-me-
diated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy 
and enhances apoptosis by promoting the release of proapoptotic 
factors from mitochondria. Cell Death Dis 2010; 1: e18.
121. Wooten MW, Geetha T, Babu JR, et al. Essential role 
of sequestosome 1/p62 in regulating accumulation of Lys63-
ubiquitinated proteins. J Biol Chem 2008; 283: 6783–9.
122. Yamamoto A, Tagawa Y, Yoshimori T, et al. Bafilomycin 
A1 prevents maturation of autophagic vacuoles by inhibiting fu-
sion between autophagosomes and lysosomes in rat hepatoma 
cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33–42.
123. Yang Z, Klionsky DJ. Mammalian autophagy: core 
molecular machinery and signaling regulation. Curr Opin Cell 
Biol 2011; 22: 124–31.
124. Yao KC, Komata T, Kondo Y, et al. Molecular response 
of human glioblastoma multiforme cells to ionizing radia-
tion: cell cycle arrest, modulation of the expression of cyclin-
dependent kinase inhibitors, and autophagy. J Neurosurg 
2003; 98: 378–84.
125. Ye Y, Shibata Y, Kikkert M, et al. Recruitment of the 
p97 ATPase and ubiquitin ligases to the site of retrotransloca-
tion at the endoplasmic reticulum membrane. Proc Natl Acad 
Sci USA 2005; 102: 14132–8.
126. Yoon YH, Cho KS, Hwang JJ, et al. Induction 
of lysosomal dilatation, arrested autophagy, and cell death 
by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol 
Vis Sci 2010; 51: 6030–7.
127. Yousefi S, Perozzo R, Schmid I, et al. Calpain-
mediated cleavage of Atg5 switches autophagy to apoptosis. 
Nat Cell Biol 2006; 8: 1124–32.
128. Zhang N, Qi Y, Wadham C, et al. FTY720 induces 
necrotic cell death and autophagy in ovarian cancer cells: a pro-
tective role of autophagy. Autophagy 2010; 6: 1157–67.
129. Zhu K, Dunner K Jr, McConkey DJ. Proteasome 
inhibitors activate autophagy as a cytoprotective response 
in human prostate cancer cells. Oncogene 2010; 29: 451–62. 
Copyright © Experimental Oncology, 2012
